DSIP Dosage Chart
Pre-bed subcutaneous protocol, short PRN cycles, and the inconsistent efficacy literature you should know about.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
DSIP (Delta Sleep-Inducing Peptide) was identified in the 1970s in animals undergoing electrically-induced sleep. Early enthusiasm for its sleep-promoting effects was followed by inconsistent clinical results — efficacy data has been variable and DSIP has never reached approved therapeutic status. It remains in use through compounding pharmacies as a sleep adjunct.
DSIP at a Glance
| Typical dose | 100–300 mcg subQ |
|---|---|
| Frequency | Pre-bed, PRN (as needed) |
| Cycle length | 1–2 weeks PRN; short courses preferred over continuous use |
| Route | Subcutaneous injection |
| FDA status | Not FDA-approved. |
| Source quality | 1970s–80s research; subsequent clinical efficacy data has been inconsistent. |
| Common vial size | 5 mg lyophilized powder |
DSIP Reconstitution Chart
How vial size, bacteriostatic water volume, and insulin-syringe units convert for DSIP. Use this to translate a prescribed mcg or mg dose into a syringe measurement.
| Vial size | Bac water | Concentration | Dose → insulin-syringe units (U-100) |
|---|---|---|---|
| 5 mg | 5 mL | 1 mg/mL (100 mcg per 0.1 mL) |
|
| 5 mg | 2 mL | 2.5 mg/mL (250 mcg per 0.1 mL) |
|
DSIP Dosing by Use Case
Commonly cited protocols vary by what DSIP is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Sleep onset / quality (PRN) | 100–300 mcg | Pre-bed, as needed | 1–2 weeks PRN | Most common use. Continuous nightly use is not standard; PRN pattern is preferred. |
| Stress modulation (off-label) | 100–200 mcg | Once daily | 1–2 weeks | Off-label and minimally validated; mechanism unclear. |
DSIP has minimal reported acute toxicity, but its inconsistent efficacy means many users see little benefit.
- •Reported side effects in practice are minimal — injection-site reactions are the most common.
- •Inconsistent efficacy data — many users report no noticeable sleep effect.
- •Long-term safety beyond short PRN courses is not well-characterized.
- •Not FDA-approved.
- •Pregnancy or breastfeeding
DSIP Dosing FAQ
Published efficacy data is inconsistent. Some users report improved sleep onset and quality; others report no effect. If you're considering DSIP, set expectations for variability — and consider that simpler interventions (sleep hygiene, melatonin, behavioral therapy for insomnia) have stronger evidence.
Most protocols specify 30–60 minutes pre-bed. Subcutaneous injection in the abdomen or thigh.
Continuous nightly use is not the standard protocol — most practitioners suggest PRN dosing in 1–2 week courses with breaks. Continuous long-term use has not been well-studied.
Sources
Related Dosage Charts
Want the full DSIP guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for DSIP therapy.
See DSIP guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.